Vabysmo for Wet Macular Degeneration: Optimal Treatment Regimen
Vabysmo (faricimab) is an excellent treatment option for wet AMD, and you should initiate therapy with 6 mg intravitreal injections every 4 weeks for the first 4 doses, then assess with OCT and visual acuity at weeks 8 and 12 after the loading phase to determine if patients can be extended to 8-week, 12-week, or 16-week intervals based on disease activity. 1
Initial Loading Phase
Start with 6 mg (0.05 mL of 120 mg/mL solution) every 4 weeks for 4 consecutive doses 1. This loading phase establishes disease control before transitioning to extended intervals.
Maintenance Dosing Strategy
After the loading phase, perform OCT and visual acuity evaluations at 8 and 12 weeks to guide your maintenance regimen. The FDA label provides three specific interval options 1:
- Option 1: Injections at weeks 28 and 44 (16-week intervals)
- Option 2: Injections at weeks 24,36, and 48 (12-week intervals)
- Option 3: Injections at weeks 20,28,36, and 44 (8-week intervals)
Most patients (60-74%) can achieve 12-16 week intervals, though some will require monthly dosing if disease activity persists 2, 3. Real-world data shows that 60.5% of treatment-naïve eyes reached 16-week intervals, and 74.4% achieved intervals ≥12 weeks 2.
When to Use Monthly Dosing
While the FDA label notes that additional efficacy was not demonstrated in most patients with every 4-week versus every 8-week dosing, continue monthly injections if persistent subretinal or intraretinal fluid remains despite extended intervals 1. In clinical practice, approximately 10-16% of eyes require switching to alternative anti-VEGF agents due to inadequate fluid control at 8-week intervals 3, 4.
Monitoring Protocol
Use OCT at each visit to assess for subretinal/intraretinal fluid and guide interval adjustments 5. The 2020 AAO guidelines emphasize OCT as the primary tool for detecting active exudation in anti-VEGF treated patients 5.
Critical Pitfalls to Avoid
Do not delay treatment initiation. Early intervention (baseline VA <0.3 logMAR) prevents vision loss in 100% of patients at 6-18 months, compared to 76.7% experiencing sustained vision loss when starting at worse baseline vision (0.6-0.7 logMAR) 6. The number needed to treat to prevent one case of ≥5-letter loss is only 3 when treating early 6.
Watch for treatment failures. If persistent exudative changes occur despite 8-week intervals, consider switching to brolucizumab or other anti-VEGF agents 3, 4. Approximately 12.5-16% of eyes may require this switch 3, 4.
Monitor for rare intraocular inflammation, which can occur after loading doses and may require treatment discontinuation 3, 4.
Comparative Effectiveness
Faricimab 6 mg every 16 weeks demonstrates superior BCVA improvement and greater CST reduction compared to aflibercept 2 mg every 8 weeks 7. However, more frequent regimens are associated with higher rates of severe adverse events, particularly ocular complications 7.
Treat-and-Extend Alternative
For previously treated eyes switching from other anti-VEGF agents, a loading phase of 3 monthly faricimab injections followed by treat-and-extend produces better outcomes than single-injection switches, with significantly longer injection intervals (mean difference 7.45 days for nAMD) 8, 9.